Our previous studies demonstrated that peripheral overexpression of angiotensin II (ANG II) type 2 receptors (AT2R) prevents hypertension-induced cardiac hypertrophy and remodeling without altering high blood pressure. This, coupled with the observations that AT2R play a role in the antihypertensive actions of ANG II type 1 receptor (AT1R) blockers (ARBs), led us to propose that peripheral overexpression of AT2R would improve the antihypertensive action of losartan (Los) in Sprague-Dawley (SD) rats made hypertensive via chronic infusion of ANG II. Here we utilized adenoviral vector-mediated AT2R gene transfer to test this hypothesis. A single intracardiac injection of adenoviral vector containing genomic AT2R (G-AT2R) DNA and enhanced green fluorescent protein (EGFP) gene controlled by cytomegalovirus (CMV) promoters (Ad-G-AT2R-EGFP; 5 ϫ 10 9 infectious units) into adult SD rats produced robust AT2R overexpression in cardiovascular tissues (kidney, lung, heart, aorta, mesenteric artery, and renal artery) that persisted for 3-5 days postinjection. By 7 days post viral injection, the overexpressed AT2R are reduced toward basal values in certain tissues (lung, kidney, and heart) and are undetectable in others (kidney and blood vessels). In two separate protocols, we demonstrated that the hypotensive effect of Los (0.125, 0.5, and 1.0 mg/kg iv) was significantly greater in the AT2R-overexpressing animals (Ϫ40.7 Ϯ 4.3, Ϫ41.8 Ϯ 4.8, and Ϫ48.1 Ϯ 2.6 mmHg, respectively) compared with control vector (Ad-CMV-EGFP)-treated rats (Ϫ12.4 Ϯ 2.2, Ϫ20.2 Ϯ 3.4, and Ϫ27.3 Ϯ 3.4 mmHg, respectively). These results provide support for a depressor role of AT2R and the proposal that combined AT2R agonist and ARB treatment may be an improved therapeutic strategy for controlling hypertension.
IT IS WELL ESTABLISHED THAT angiotensin II (ANG II) has a major role in the control of blood pressure and cardiovascular function and that its hyperactivity leads to hypertension and cardiovascular disease (19) . The physiological actions of ANG II include vasoconstriction and increases in aldosterone secretion, sympathetic nerve activity, and water and sodium intake (19) . In pathological situations such as hypertension, the vasoconstrictor actions of ANG II are exacerbated, and this peptide also displays a powerful trophic action and contributes to cardiac hypertrophy and fibrosis (37, 40) . These physiological and pathological actions of ANG II are mediated via its type 1 receptors (AT 1 R) (19) , and AT 1 R blockers (ARBs) such as losartan (Los; Cozaar) are in common use as antihypertensive agents (11, 51) . 1 In comparison with the AT 1 R, a role for ANG II type 2 receptors (AT 2 R) in the control of blood pressure and cardiovascular function is not established. A number of studies have failed to demonstrate any role of endogenous AT 2 R in blood pressure regulation (15, 35, 42, 48) , but they may have been hampered by the fact that AT 2 R exist in adult cardiovascular tissues in low concentrations (19) . An increasing amount of evidence now indicates that ANG II can influence cardiovascular function via its AT 2 R, producing a vasodilator action that is opposite to the vasoconstrictor effect of ANG II via AT 1 R (12). This AT 2 R-mediated vasodilator action was more apparent in situations where the renin-angiotensin system was upregulated. For example, Carey and colleagues (12, 14) demonstrated that, in the kidney, ANG II acts at the AT 2 R to stimulate a vasodilator cascade of bradykinin, nitric oxide, and cyclic guanosine 5Ј-monophosphate, which is tonically activated only during conditions of increased ANG II, such as sodium depletion and ANG II infusion-induced hypertension. It is now apparent that these conditions produce increased sensitivity and/or expression of vascular and renal AT 2 R (9, 25, 46) . The vasodilator action of ANG II via AT 2 R was also revealed in some studies in the presence of ARB to prevent the vasoconstrictor actions of the peptide (6, 13, 17, 23, 54) . However, other studies have demonstrated that the hypotensive action of the ARB Los is not dependent on AT 2 R activation (16, 30) . The controversy that surrounds the vasodilatory effect of ANG II via AT 2 R also extends to the site of action. In addition to the above renal vasodilator actions of ANG II, other studies (8, 28, 32, 36) have demonstrated AT 2 Rmediated vasodilatory actions of ANG II in resistance microvessels and in large capacitance vessels. By contrast, another study (41) indicated that coronary but not renal AT 2 R stimulation results in vasodilation.
The above studies that suggest a role of native AT 2 R in blood pressure regulation are supported by experiments using transgenic animal models. For example, transgenic mice that overexpress AT 2 R within aortic vascular smooth muscle cells exhibit vasodilation in response to chronic infusion of ANG II (49) . It is also clear that AT 2 R knockout mice display increased basal blood pressures and increased vasoconstrictor responses to ANG II via AT 1 R (3, 26, 27, 31, 45) . These studies are supported by our previous gene transfer studies, which demonstrated that overexpression of AT 2 R-antisense in cardiovascular tissues of neonatal normotensive rats, and subsequent knockdown of AT 2 R, resulted in elevated blood pressure in these animals during adulthood (52) . Collectively, these data imply that AT 2 R normally antagonize the AT 1 R-mediated rise in blood pressure. However, the increase in pressor sensitivity may also be explained by the increased vascular AT 1 R expression in AT 2 R knockout mice (47) .
On the basis of the available data, it is difficult at this point to assign a role for AT 2 R in hypertension. However, a number of studies have reported that the expression of AT 2 R is increased following renal ablation and in pathological conditions such as vascular injury, cardiac remodeling, congestive heart failure, and myocardial infarction (2, 29, 39, 50) . Furthermore, it appears that the expressed AT 2 R have a protective role within cardiovascular and renal tissues (29, 39, 50) . In concert with these findings, a virally mediated gene transfer approach allowed us to demonstrate that overexpression of AT 2 R in cardiac tissues attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats (SHR) and in normotensive rats made hypertensive by ANG II infusion (21, 38) . Nonetheless, there are also conflicting data that argue that the AT 2 R elicits cardiac growth and does not antagonize AT 1 R-mediated cardiac hypertrophy (5, 18) . From a more clinical perspective, a recent study has demonstrated that, in patients with systemic hypertension, there is an association between left ventricular hypertrophy and a common intronic polymorphism of the AT 2 R gene, which results in less effective transcription (4) . This supports the idea of an antigrowth/cardioprotective role of the AT 2 R.
Therefore, the actions of AT 2 R described to this point are largely counteractive to those of ANG II via AT 1 R. A number of studies have also suggested that the decrease in blood pressure produced by ARBs is partially mediated by high circulating levels of ANG II acting via AT 2 R (20, 44) . In fact, all of the available clinical data suggest that the beneficial effects of ARBs on hypertension and cardiovascular disease are due in part to their antagonism of the AT 1 R and in part by activation of the AT 2 R as a result of their ability to increase circulating ANG II (22, 43, 53) . Considering the conflicting reports in this area and that cardiovascular tissues of adult animals contain only low levels of AT 2 R, we set out to test this idea in a novel way by overexpressing the AT 2 R in cardiovascular tissues. The rationale was that we would be able to enhance their participation to a level that can be physiologically studied. Our data indicate that increased peripheral expression of AT 2 R produced by virally mediated gene delivery is associated with enhancement of the hypotensive action of the ARB Los.
MATERIALS AND METHODS

Animals
For the cell culture experiments described here we utilized neonatal Sprague-Dawley (SD) rat pups, derived from our breeding colony. For the physiological experiments, we used adult male SD rats. Breeders and adult male rats were purchased from Charles River Farms (Wilmington, MA). All experimental procedures were approved by the University of Florida Institutional Animal Care and Use Committee (protocols 0746 and 0758). 
Materials
Recombinant Adenoviral Constructs
Preparation of the adenoviral constructs [adenoviral vector containing enhanced green fluorescent protein gene controlled by a cytomegalovirus promoter (Ad-CMV-EGFP) and adenoviral vector containing genomic AT 2R (G-AT2R) DNA with introns 1 and 2 and the encoding region and enhanced green fluorescent protein gene controlled by cytomegalovirus promoters (Ad-G-AT2R-EGFP)] was performed exactly as detailed previously (34) .
Adenovirally Mediated Gene Transduction
To assess adenovirally mediated transduction, Ad-G-AT2R-EGFP and Ad-CMV-EGFP [both 5 ϫ 10 9 infectious units (ifu)/rat] were injected intracardially (left ventricle) into SD rats (n ϭ 6/group) using the same procedures as detailed previously by our group (21, 38, 40, 52) . On days 3, 5, and 7 after the injections, two rats from each group were euthanized and the liver, heart, kidney, lung, aorta, and mesenteric and renal arteries were removed. All samples were immediately frozen in dry ice and stored at Ϫ80°C. The biodistribution of adenoviral vector and the expression of AT 2R in each tissue were determined as described in the following two sections.
RT-PCR Analysis of AT 2R Transgene Expression in Rat Tissues
The forward primer and the reverse primer were designed from AT2R and simian virus 40 poly(A), respectively, to amplify a specific fragment of the transduced exogenous AT2R cDNA. The primers were as follows: AT2-F (forward primer): 5Ј-ACAGAATTACCCGT-GACCAA-3Ј; poly(A)-R (reverse primer): 5Ј-GGCTGATTATGAT-CAGTTATC-3Ј.
Total RNA was prepared from the transduced tissues using an RNeasy kit. RT-PCR reactions were performed using a OneStep RT-PCR kit under the following conditions: 1 cycle of 50°C for 30 min, 95°C for 15 min; 40 cycles of 94°C for 40 s, 50°C for 1 min, 72°C for 2 min, and 1 cycle of 72°C for 8 min. PCR products were separated by electrophoresis on a 2.0% agarose gel and identified by restriction endonuclease analysis.
Real-Time PCR for the Detection of Adenoviral Vectors in Rat Tissues
Oligonucleotide primers and probe specific for EGFP were designed to detect the Ad vectors in rat tissues using Primer Express. The primers and probe used were as follows: EGFP-F (forward): 5Ј-AGAACGGCATCAAGGTGAAC-3Ј; EGFP-R (reverse): 5Ј-TGCTCAGGTAGTGGTTGTC-3Ј; EGFP probe: 5Ј-FAMCCGGCA-GATAAGCAT-TAMRA-3Ј.
DNA was extracted from the frozen tissue samples using DNeasy tissue kits. The procedures used were according to the manufacturer's instructions of the kits. About 10 mg tissue of each sample was used for extraction of total DNA.
Real-time PCR was performed according to the protocols of the manufacturer with an ABI Prism 7000 HT Detection System (Applied Biosystems) using TaqMan PCR Master Mix. Relative quantification was performed using the comparative method as described in Applied Biosystems User Bulletin 2. No template controls were used to monitor for any contaminating amplification.
Preparation of Cardiac Fibroblast Cultures
Neonatal rat cardiac fibroblasts were isolated using a method adapted from Zhang et al. (56) . Briefly, 5-day-old SD rat pups were anesthetized by halothane inhalation. Heart ventricles were removed by blunt dissection, cleaned of atria and adherent tissue, and washed in ice-cold PBS. Ventricles were then minced with scissors and resuspended in 20 ml of 1% collagenase and incubated at 37°C for 2 h. The suspension was centrifuged at 2,000 rpm for 5 min, and the supernatant was aspirated. The pellet was resuspended in 20 ml of 0.25% trypsin and incubated at 37°C for 1 h. This suspension was centrifuged as before, and the pellet was resuspended in 10 ml of growth media consisting of DMEM supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 5 g/ml ascorbic acid. This suspension was plated in a 75-cm 2 flask. Cells were maintained with a 95% air-5% CO2 gas mixture in a 37°C humidified incubator. Media was changed every 48 h until confluence. Cells were split using a standard trypsin method and seeded into 12-well plates at 3,000 cells/cm 2 . Only cells in passages 2 and 3 were used for experiments.
ANG II Receptor Binding
Cardiac fibroblasts grown in 12-well plates were transduced with 4.0 ϫ 10 5 ifu per well of either Ad-CMV-EGFP or Ad-G-AT2R-EGFP for 24 h or were incubated with PBS for the same time period. This was followed by analysis of ANG II receptor binding as described by us previously (34) . In brief, transduced cultures were washed with PBS (pH 7.4) and incubated for 1 h at room temperature with 0. 
In Vivo Physiological Procedures and Measurements
Protocol 1. Fourteen male SD rats weighing 390 -430 g were implanted with subcutaneous osmotic minipumps (model 2004 Alzet; Durect, Cupertino, CA) delivering ANG II at 152.0 Ϯ 1.6 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 for 4 wk. After three and a half weeks of treatment, rats were anesthetized by inhalation of metaphane, and Ad-CMV-EGFP (n ϭ 6 rats) or Ad-G-AT 2R-EGFP (n ϭ 8 rats) was delivered by a single intracardiac injection (1.1 ml of 5 ϫ 10 10 ifu/ml). Two days following viral delivery, animals were anesthetized by intramuscular injection of a mixture of ketamine, xylazine, and acepromazine (30, 6 , and 1 mg/kg, respectively). A polyethylene cannula (PE-50; Clay Adams, Parsippany, NY) was inserted into the carotid artery to allow direct blood pressure monitoring, and a silicone elastomer cannula (Helix Medical, Carpinteria, CA) was inserted into the jugular vein to allow for acute intravenous injections. Both cannulas were filled with heparinized saline (40 U/ml) and sealed with stylets. Animals were allowed to recover for 24 h, at which time direct blood pressure recordings were taken from awake, freely moving animals with the use of a liquid pressure transducer interfaced to a PowerLab signal transduction unit (ADInstruments, Colorado Springs, CO), interfaced to a PC computer. After a control period of 45-60 min, animals were administered Los at a dose of 1 mg/kg iv, and blood pressure was recorded over the next 2 h. Data were analyzed using the Chart 4.0 program supplied by ADInstruments.
Protocol 2. Eighteen male SD rats weighing 175-200 g were implanted with telemetry transducers (Data Sciences, St. Paul, MN) into the abdominal aorta under isoflurane anesthesia [O 2-isoflurane (2%) mixture] as described previously (21) . Following 1 wk of recovery and stabilization, each rat received an Alzet osmotic minipump (model 2004), inserted subcutaneously under isoflurane anesthesia as above, to deliver ANG II at 200 ng⅐kg Ϫ1 ⅐min Ϫ1 for ϳ4 wk. Mean arterial pressure (MAP) and heart rate were recorded via the telemetry devices, with raw data analyzed using Dataquest IV software (Data Sciences). Sixteen days following implantation of the minipumps, rats were randomly assigned to three groups. Each rat was anesthetized with the above O 2-isoflurane (2%) mixture and received a single intracardiac injection (1.0 ml of 5 ϫ 10 9 ifu) of either Ad-CMV-EGFP (GFP; n ϭ 7 rats), Ad-G-AT2R-EGFP (AT2R; n ϭ 7 rats), or 0.9% saline (n ϭ 4 rats). This was followed 1 day later by implantation of a silicone elastomer cannula (Helix Medical) into the jugular vein, as in protocol 1. At 3 days after the viral or 0.9% saline injections, rats received an intravenous injection of 1.0 mg/kg body wt of Los in a volume of 1 ml. MAP was recorded via telemetry before and during the 2 h following Los administration. This procedure was repeated using respective intravenous doses of 0.125 and 0.5 mg/kg body wt of Los on day 4 after the viral or 0.9% saline injections. Note that the second injection of Los (0.5 mg/kg) was made at least 3 h after MAP had returned to baseline following the first Los injection (0.125 mg/kg).
On day 5 after viral injections, rats from the GFP and AT 2R groups were anesthetized with a mixture of ketamine, xylazine, and acepromazine as above in protocol 1. Anesthetized rats received an intravenous injection of 1.0 mg/kg body wt of Los in a volume of 1 ml, followed 20 min later by intravenous infusion of 1.0 mg/kg body wt for 30 min of the AT 2R-selective blocker PD-123,319. MAP was recorded via telemetry before and for 30 min following PD-123,319 administration.
At 7 days after the viral injections (at which time AT 2R expression has declined toward control values), conscious rats received an intravenous injection of 0.5 mg/kg body wt of Los in a volume of 1 ml, and MAP was recorded via telemetry as above.
Data Analysis
Data are expressed as means Ϯ SE. Statistical significance was evaluated with the use of a one-or two-way ANOVA as appropriate, followed by a Bonferroni post hoc test to compare individual means. Differences were considered significant at P Ͻ 0.05; individual P values are noted in the figure legends.
RESULTS
Adenovirally Mediated Overexpression of AT 2 R
Our previous studies demonstrated that Ad-G-AT 2 R-EGFP elicits significant expression of AT 2 R within various cell lines (e.g., C2C12 mouse muscle myoblasts, NIH/3T3 fibroblasts, CATH.a locus ceruleus tumor cells) (34) . Here, in the first set of experiments we tested the ability of Ad-G-AT 2 R-EGFP (Fig. 1B) . Neither Ad-CMV-EGFP nor Ad-G-AT 2 R-EGFP produced any change in the levels of AT 1 R-specific binding (Fig. 1B) . Similar results were obtained from cultured cardiac myocytes, i.e., Ad-G-AT 2 R-EGFP provided robust transduction and resulted in a large increase in the level of AT 2 R-specific binding, with no changes in AT 1 R-specific binding (data not shown). These data are consistent with our previous studies that indicate that lentivirally mediated overexpression of AT 2 R in rat heart produces no changes in AT 1 R levels in cardiomyocytes (38) .
The above findings indicate that Ad-G-AT 2 R-EGFP is highly efficient at increasing the expression of AT 2 R in cardiac cells, without having any effect on the level of AT 1 R binding. Next we tested whether this vector produces expression of AT 2 R within peripheral tissues following intracardiac administration. SD rats received an intracardiac injection of either Ad-G-AT 2 R-EGFP (5 ϫ 10 9 ifu; n ϭ 6 rats) or Ad-CMV-EGFP (5 ϫ 10 9 ifu; n ϭ 6 rats). At days 3, 5, and 7 after the injections, two rats from each group were euthanized, and the liver, heart, kidney, lung, aorta, mesenteric artery, and renal artery were removed for detection of adenoviral vectors and analysis of AT 2 R transgene expression. The data presented in Fig. 2 demonstrate that viral (Ad-G-AT 2 R-EGFP) DNA was detected in all of the tissues examined at 3 and 5 days after intracardiac injections. At day 7, each tissue demonstrated reduced level of Ad-G-AT 2 R-EGFP DNA. This ranged from reductions of (for example) ϳ80-fold from day 3 to day 7 in the liver to ϳ16-fold in the mesenteric artery over the same time period (Fig. 2) . Thus viral DNA persists within all of the infected tissues at 7 days post intracardiac injections, albeit at lower levels. However, the expression pattern obtained for the AT 2 R transgene (i.e., the overexpressed AT 2 R) is different. The data in Fig. 3 show that AT 2 R transgene was expressed in liver, heart, lung, aorta, kidney, and mesenteric arteries at 3 and 5 days post viral injections. Thus Ad-G-AT 2 R-EGFP transduces and elicits AT 2 R overexpression in tissue sites such as heart, kidney, and blood vessels that express native AT 2 R (19). AT 2 R transgene persists in the liver and lung at 7 days but is sharply reduced according to real-time RT-PCR analyses (not shown). In addition, it is clear from Fig. 3 that the AT 2 R transgene is either reduced (heart) or undetectable (kidney, aorta, and mesenteric artery) at day 7 after viral injections. The reduction in AT 2 R transgene expression may reflect silencing of the CMV promoter, as observed in other tissues following adenoviral administration (7, 10) . On the basis of this expression pattern, analyses of the effects of the AT 1 R antagonist Los on MAP in AT 2 R-overexpressing animals were assessed at 3 to 5 days following viral administration.
Enhanced Hypotensive Action of Los in SD Rats
Overexpressing AT 2 
R
The effects of overexpression of AT 2 R on Los-induced decreases in blood pressure were assessed via two separate experimental protocols as set out in MATERIALS AND METHODS. Protocol 1. In this protocol, SD rats that were implanted subcutaneously with osmotic minipumps containing ANG II (152.0 Ϯ 1.6 ng⅐kg Ϫ1 ⅐min Ϫ1 ) developed a significant increase in blood pressure within 2-3 wk of treatment. During the 3rd wk of treatment, animals received a single intracardiac 9 ifu (per rat) of Ad-G-AT2R-EGFP, and on days 3, 5, and 7, two rats were euthanized, organs were collected, and DNA was extracted. The levels of Ad-G-AT2R-EGFP DNA in liver, heart, kidney, lung, aorta, mesenteric artery (Mes. Art.), and renal artery were determined by real-time PCR normalized to cellular DNA, as described in MATERIALS AND METHODS. The bars represent mean Ϯ SE values of data from two rats.
injection of either Ad-CMV-EGFP or Ad-G-AT 2 R-EGFP (1.1 ml of 5 ϫ 10 10 ifu/rat). Basal mean blood pressures (analyzed via direct monitoring from the carotid artery) were not different between the animals treated with Ad-CMV-EGFP versus the Ad-G-AT 2 R-EGFP vector-treated rats (124.9 Ϯ 8.5 and 125.7 Ϯ 6.6 mmHg, respectively). Heart rate values were also not different between the Ad-CMV-EGFP and Ad-G-AT 2 R-EGFP treatments (349.1 Ϯ 49.4 and 384.8 Ϯ 49.1 beats/min, respectively). Blood pressure responses to acute injection of Los (1 mg/kg iv) were significantly enhanced in animals treated with the Ad-G-AT 2 R-EGFP virus. MAP decreased by 9.0 Ϯ 4.0 mmHg in the Ad-CMV-EGFP-treated rats and by 29.5 Ϯ 5.9 mmHg in the Ad-G-AT 2 R-EGFP-treated rats in response to Los, as shown in Fig. 4 .
Protocol 2. Having established in protocol 1 that rats that overexpress AT 2 R display an enhanced hypotensive response to intravenously administered Los, we had three objectives in protocol 2: 1)to determine the hypotensive effects of different doses of Los in the AT 2 R-overexpressing rats; 2) to determine the hypotensive effect of Los following the return of AT 2 R toward basal values; and 3) to investigate whether the enhanced hypotensive action of Los involved activation of AT 2 R. Subcutaneous infusion of ANG II (200 ng⅐kg Ϫ1 ⅐ min Ϫ1 ) via osmotic minipump produced a time-dependent increase in MAP in all rats within 2 wk. Intracardiac administration of either Ad-CMV-EGFP, Ad-G-AT 2 R-EGFP (both 1.0 ml of 5 ϫ 10 9 ifu/rat), or 0.9% saline produced no significant change in MAP (156.2 Ϯ 3.1, 151.2 Ϯ 3.8, and 157.3 Ϯ 3.3 mmHg, respectively) or heart rate (335.8 Ϯ 3.7, 341.7 Ϯ 3.7, and 323.9 Ϯ 3.1 beats/min, respectively) 3 days later, at which time AT 2 R expression is maximal (Fig. 3) . Intravenous injection of Los (0.125, 0.5, or 1.0 mg/kg) into the Ad-CMV-EGFP-treated rats produced significant dose-related decrease in MAP (Fig.  5A) . A similar significant decrease in MAP was produced by Los (1.0 mg/kg iv) in the rats that had been injected intracardially with 0.9% saline (Fig. 5A ). This hypotensive action of Los was significantly enhanced, at all three doses, in the Ad-G-AT 2 R-EGFP-treated rats (Fig. 5A) . However, in the Ad-G-AT 2 R-EGFP-treated rats, the effect of Los was not particularly dose related. It is possible that the increased levels of AT 2 R in this group have shifted the response curve such that it would take a broader range of doses to see a dose-dependent action of Los. Closer inspection of the data also revealed that the decrease in MAP produced by Los persisted for a longer period in the Ad-G-AT 2 R-EGFP-treated rats when compared with the control (Ad-CMV-EGFP) group of animals. This is illustrated by the example given in Fig. 5B , which shows the Fig. 3 . AT2R transgene expression in rat tissues after intracardiac administration of adenoviral constructs. Rats were injected intracardially (left ventricle) with adenoviral constructs (5 ϫ 10 9 ifu/rat) as described in MATERIALS AND METHODS, and 3, 5 and 7 days later, tissues were removed for assessment of AT2R transgene expression. The forward primer is from the AT2R cDNA and the reverse primer is from simian virus 40 poly(A). For each tissue, the lanes are as follows: rats injected with Ad-G-AT2R-EGFP (Ad-AT2R at 3, 5 and 7 days); rats injected with Ad-CMV-EGFP (Ad-GF at 3 days); NT is a no template control. M, 100 bp ladder. 1 mg/kg iv) in the Ad-G-AT2R-EGFP (n ϭ 8) and Ad-CMV-EGFP (n ϭ 6) groups of rats. *P ϭ 0.0181.
hypotensive action of Los (0.5 mg/kg iv) as a function of time. Seven days after injection of the viral vectors, at which time the overexpressed AT 2 R are no longer detectable in kidney and blood vessels (Fig. 3) , there was no significant difference in the effects of Los (0.5 mg/kg iv) between the Ad-CMV-EGFP-and Ad-G-AT 2 R-EGFP-treated rats (Fig. 5C) .
To determine whether the hypotensive action of Los included an AT 2 R influence, we tested the effects of AT 2 R antagonism during the reduction in MAP produced by Los. In rats that had received either Ad-CMV-EGFP or 0.9% saline intracardially 5 days earlier, Los (1.0 mg/kg iv) produced a fall in MAP that was unaltered by infusion of the AT 2 R-selective blocker PD-123,319 (1.0 mg/kg iv for 30 min) (Fig. 6) . However, in the Ad-G-AT 2 R-EGFP-treated rats, similar administration of PD-123,319 prevented the enhanced hypotensive action of Los (1.0 mg/kg iv) (Fig. 6) . Upon cessation of PD-123,319 infusion, the MAP of the Ad-G-AT 2 R-EGFPtreated rats began to fall again (Fig. 6 ).
DISCUSSION
The major findings of this study are the following: 1) the Ad-G-AT2R-EGFP viral construct utilized here produces high levels of AT 2 R expression in cardiac cells and transduces peripheral tissues following intracardiac injection; 2) the transduction of AT 2 R in peripheral tissues is transient, reaching a peak at 3 to 5 days; at 7 days post viral injection, the overexpressed AT 2 R are reduced toward basal values in certain tissues (lung, kidney, and heart) and are undetectable in others (kidney and blood vessels); 3) the increased expression of AT 2 R produces no alterations in AT 1 R expression; 4) in two separate protocols, peripheral overexpression of AT 2 R via Ad-G-AT 2 R-EGFP does not alter basal MAP in the rats made hypertensive by infusion of ANG II but enhances the hypotensive action of Los in rats made hypertensive via subcutaneous infusion of ANG II; 5) the enhanced hypotensive action of Los is no longer apparent when systemic AT 2 R have returned almost to control (basal) values; and 6) the enhanced hypotensive action of Los produced by Ad-G-AT 2 R-EGFP is reversed by the AT 2 R blocker PD-123,319.
Thus the Ad-G-AT 2 R-EGFP system that has been used here to transiently overexpress AT 2 R in peripheral tissues has been valuable in that it has helped to provide further evidence for a depressor role of the AT 2 R. This is consistent with previous pharmacological, gene knockout, and overexpression approaches that have argued for a blood pressure-lowering role of AT 2 R (3, 6, 13, 17, 23, 26, 27, 31, 45, 54) . More importantly, Fig. 5 . Hypotensive action of different doses of Los in AT2R-transduced rats. SD rats were instrumented with telemetry transducers and administered ANG II via subcutaneous infusion as described under protocol 2. Sixteen days later, at which time all rats exhibited significant hypertension, they were randomly assigned to 3 groups and received a single intracardiac injection (1.0 ml of 5 ϫ 10 9 ifu/rat) of either Ad-CMV-EGFP (GFP; n ϭ 7 rats), Ad-G-AT2R-EGFP (AT2R; n ϭ 7 rats), or 0.9% saline (Sal; n ϭ 4 rats). At 3 and 4 days after the viral injections, rats were administered Los (0.125, 0.5 or 1.0 mg/kg iv) as described in Protocol 2. A: change in MAP over a 2-h recording period produced by the different doses of Los in the Sal, GFP, and AT2R-treated rats. Data are means Ϯ SE. *P Ͻ 0.05 vs. the respective control (Sal/ GFP) groups. B: change in MAP every 30 min over the 2-h recording period produced by 0.5 mg/kg Los in the GFP and AT2R-treated groups. Data are means Ϯ SE. *P Ͻ 0.05 vs. the respective control (GFP) period. C: change in MAP over a 2-h recording period produced by Los (1.0 mg/kg iv) on day 7 after viral transduction in the Sal, GFP, and AT2R-treated rats. Data are means Ϯ SE. the ability to transiently increase the expression of AT 2 R in cardiovascular tissues has revealed that the hypotensive action of Los can be increased during elevated expression of AT 2 R. These findings provide solid evidence to support the idea that concurrent activation of AT 2 R along with AT 1 R blockade may be beneficial for hypertensive patients (43, 53) . The results presented here also complement previous work from our lab that demonstrated that reduced expression of AT 2 R resulted in an increase in blood pressure (52) .
Despite the above findings, a number of important questions remain. First and foremost concerns the site(s) of action of AT 2 R in enhancing the hypotensive action of Los. The gene systemic delivery approach that is used here, which involves intracardiac injections of viral vectors, produces overexpression of AT 2 R at a variety of peripheral tissue sites, including blood vessels and the heart and kidney (Figs. 2 and 3) . Thus it is difficult to assess which of these sites may be important for the AT 2 R action in enhancing the effects of Los. On the basis of the current literature, we might expect that vasodilator actions of the expressed AT 2 R involve vascular actions at the kidney or at specific vessel beds (8, 28, 32, 36) , and targeted gene delivery to blood vessels or other cardiovascular organs would help to reveal which site or sites are more important for this AT 2 R effect. However, even though the particular site of action of AT 2 R in increasing the antihypertensive action of Los is not known, the fact remains that AT 2 R are effective in this regard. A second issue relates to the length of time that the AT 2 R are overexpressed within cardiovascular tissues. The Ad5 vector system employed here allows for transient overexpression that is useful in experimental situations in that it allows determination of physiological parameters during elevated levels of AT 2 R and then again when AT 2 R have returned toward control levels. Such a system may prove useful clinically where transient expression of a protein is required but only if the immune response produced by Ad vectors can be tempered. Clearly, it will be interesting to determine whether longer-term overexpression of AT 2 R can result in a greater and more sustained enhancement of the hypotensive action of Los. We plan to achieve this through the use of an adeno-associated virus-CMV-AT 2 R construct that has been developed in our laboratory. Combined use of this construct along with targeted delivery to specific organs/sites may allow us to identify the areas that are most important in this AT 2 R action. A third issue concerns the mechanism of action of AT 2 R in lowering MAP. The data presented in the current study do not allow for us to determine the relative contributions of AT 2 R-mediated alterations in cardiac output and total peripheral resistance to the fall in MAP. However, it appears from the literature that either (or both) mechanism(s) may mediate the observed blood pressure effects of AT 2 R overexpression (3, 23, 33, 55) .
Whereas the data demonstrate that overexpression of AT 2 R can enhance the decrease in MAP produced by AT 1 R antagonism, the mechanisms involved are not established. One possibility is that, with the AT 1 R blocked, the increased levels of plasma ANG II derived from the subcutaneous administration are free to act at the AT 2 R and produce a depressor action. In addition, it is well known that AT 1 R blockade via Los results in high circulating levels of ANG II because of a lack of feedback inhibition at kidney juxtaglomerular cells and increased renin secretion (20, 44) . Thus we may speculate that the increased vasodilator action of Los in the AT 2 R-overexpressing (Ad-G-AT2R-EGFP-treated) rats is due to the raised endogenous levels of ANG II (as well as the exogenous subcutaneously delivered ANG II) acting at the overexpressed AT 2 R. Either case is certainly supported by our data (Fig. 6) , which demonstrate that the enhanced hypotensive action of Los in these rats is seen acutely and is rapidly reversed by the AT 2 R-selective blocker PD-123,319. The observation that PD-123,319 has no effect on the Los-induced decreases in MAP in the control ANG II-infused groups of rats [0.9% saline and Ad-CMV-EGFP] suggests that, in the experimental model of hypertension used here, activation of native AT 2 R is not at a sufficient level to contribute to the hypotensive action of Los. This is consistent with a report that demonstrates that AT 2 R do not contribute to the blood pressure-lowering effects of Los in SHR and two-kidney, one-clip hypertensive rats (20) .
Another contributing factor that may be considered is that the increased levels of AT 2 R bind to or dimerize with the AT 1 R (1) in cardiovascular tissues, further preventing the pressor action of ANG II via AT 1 R but allowing free AT 2 R to respond to ANG II with a vasodilator action. However, we think that this possibility is unlikely since the Ad-G-AT 2 R-EGFP induced-increased expression of AT 2 R does not alter AT 1 R binding, at least in vitro (Fig. 1) . Furthermore, if AT 2 R/ AT 1 R dimers had a role to play in this response, we might expect Ad-G-AT 2 R-EGFP to decrease basal MAP. However, this is clearly not the case since basal MAP and heart rate are unaltered in the AT 2 R-overexpressing rats when compared with both control groups.
To summarize, the present data support previous findings that describe a depressor role of AT 2 R. However, the observation that increased expression of AT 2 R in cardiovascular tissues does not alter basal MAP may indicate that even the higher levels of this receptor are not adequate to offset or influence the actions of ANG II via AT 1 R or that the increased expression produced here is too transient. Rather, it appears that AT 2 R actions are unmasked in situations where AT 1 R activity is depressed, in this case by the AT 1 R antagonist Los.
